EA201591111A1 - Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида - Google Patents

Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида

Info

Publication number
EA201591111A1
EA201591111A1 EA201591111A EA201591111A EA201591111A1 EA 201591111 A1 EA201591111 A1 EA 201591111A1 EA 201591111 A EA201591111 A EA 201591111A EA 201591111 A EA201591111 A EA 201591111A EA 201591111 A1 EA201591111 A1 EA 201591111A1
Authority
EA
Eurasian Patent Office
Prior art keywords
themosolomide
contained
dosage form
polymeric particles
composition
Prior art date
Application number
EA201591111A
Other languages
English (en)
Inventor
Екатерина Василенко
Евгений Воронцов
Евгений Северин
Виктор Гуленко
Максим Митрохин
Максим Юрченко
Original Assignee
Ой Филана Лтд.
Юникемфарм Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ой Филана Лтд., Юникемфарм Лтд. filed Critical Ой Филана Лтд.
Publication of EA201591111A1 publication Critical patent/EA201591111A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармакологии и медицине и более конкретно - к противоопухолевой лекарственной композиции с замедленным высвобождением, полученной на основе биоразлагаемого полимера на основе молочной и гликолевой кислот (PLGA). Композиция включает темозоломид (TMZ), в качестве активного ингредиента, а также включает поверхностно-активный материал и криопротектор, в качестве составных частей наночастиц.
EA201591111A 2012-12-10 2013-12-10 Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида EA201591111A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735089P 2012-12-10 2012-12-10
FI20126281A FI20126281L (fi) 2012-12-10 2012-12-10 Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
PCT/FI2013/051151 WO2014091078A1 (en) 2012-12-10 2013-12-10 Polymeric particles-based temozolomide dosage form

Publications (1)

Publication Number Publication Date
EA201591111A1 true EA201591111A1 (ru) 2016-04-29

Family

ID=50933803

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591111A EA201591111A1 (ru) 2012-12-10 2013-12-10 Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида

Country Status (4)

Country Link
US (1) US20150328169A1 (ru)
EA (1) EA201591111A1 (ru)
FI (1) FI20126281L (ru)
WO (1) WO2014091078A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019071229A1 (en) 2017-10-06 2019-04-11 Research Cancer Institute Of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR PREVENTING AND / OR TREATING NEOPLASMS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
US10555911B2 (en) * 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
EP2662079A1 (en) * 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells

Also Published As

Publication number Publication date
US20150328169A1 (en) 2015-11-19
WO2014091078A1 (en) 2014-06-19
FI20126281L (fi) 2014-06-11

Similar Documents

Publication Publication Date Title
EA201590583A1 (ru) Способ получения терапевтических наночастиц
MX350589B (es) Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia.
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
WO2012101639A3 (en) Nanoparticles based for dermal and systemic delivery of drugs
CL2023002345A1 (es) Composiciones y métodos para fabricar microparticulas de proteína.
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
IN2014DN06529A (ru)
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
MX2022010831A (es) Formulaciones inyectables de liberacion extendida que comprenden un agente activo de isoxazolina, metodos y usos de las mismas.
MX359119B (es) Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas.
EA201591111A1 (ru) Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
UA112540C2 (uk) Плівкова лікарська форма, яка містить вільну основу силденафілу, і спосіб її отримання
WO2013013038A3 (en) Doping agents and polymeric compositions thereof for controlled drug delivery
EP4360621A3 (en) Formulations of bendamustine
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
EA201890436A1 (ru) Жидкая полимерная система доставки для длительного введения лекарственных средств
MY174729A (en) Pharmaceutical combination drug
CO6382109A2 (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
TN2015000498A1 (en) Modified release formulation
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением